A new era in the treatment of primary pulmonary hypertension
暂无分享,去创建一个
[1] G. Simonneau,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study ☆ , 2002 .
[2] D. Badesch,et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[3] M. Hoeper,et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.
[4] Adrian M Heilbut,et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor , 2000, Nature Medicine.
[5] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[6] D. Stewart,et al. Cell-based gene transfer to the pulmonary vasculature: Endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. , 1999, American journal of respiratory cell and molecular biology.
[7] Y. Okano,et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.
[8] N. Voelkel,et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. , 1999, The Journal of clinical investigation.
[9] J. Orens,et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. , 1998, Circulation.
[10] T. Evans,et al. Nitric oxide, the biological mediator of the decade: fact or fiction? , 1997, The European respiratory journal.
[11] W. Auger,et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. , 1996, Chest.
[12] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[13] A Giaid,et al. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.
[14] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[15] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[16] S. Rich,et al. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.
[17] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[18] D. Stewart,et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.
[19] Inda,et al. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .